To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)

NCT04661007 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Hodgkins Lymphoma
Diffuse Large B-cell Lymphoma

Interventions

DRUG: tafasitamab
DRUG: lenalidomide
DRUG: parsaclisib
DRUG: R-CHOP

Sponsor

Incyte Biosciences Japan GK